PUBLISHER: Global Insight Services | PRODUCT CODE: 1634059
PUBLISHER: Global Insight Services | PRODUCT CODE: 1634059
The animal model market is anticipated to expand from $2.4 billion in 2023 to $5.0 billion by 2033, reflecting a compound annual growth rate (CAGR) of 7.3%.
The animal model market encompasses the development and use of non-human animals for testing and research to understand biological and pathological processes, primarily in drug development and biomedical research. This market includes genetically engineered models, disease-specific models, and services that facilitate preclinical trials, contributing to advancements in healthcare by providing critical insights into human diseases and therapeutic efficacy.
The animal model market is witnessing robust growth, primarily driven by advancements in biomedical research and drug development. Rodent models, particularly mice and rats, dominate the market due to their genetic similarities to humans and cost-effectiveness. Non-human primates, though less prevalent, are the second-highest performing sub-segment, reflecting their critical role in complex disease modeling and translational research. The North American region leads the market, supported by well-established research infrastructure and substantial funding for life sciences. Europe follows as the second-highest performing region, driven by increasing investments in research and development and a supportive regulatory environment. Within these regions, the United States and Germany are the standout countries, showcasing significant advancements in genetic engineering and personalized medicine. Emerging markets in Asia-Pacific, notably China and India, are gaining momentum, fueled by growing biotechnology sectors and increased focus on healthcare innovation. This dynamic landscape presents lucrative opportunities for stakeholders across the animal model market.
In 2023, the market demonstrated robust segmentation with the rodent models holding a commanding 50% market share, driven by their extensive use in biomedical research. Non-rodent models, including canines and primates, accounted for 30%, reflecting their critical role in complex disease studies. Zebrafish models, gaining traction due to their genetic similarity to humans, captured 15%. The remaining 5% was comprised of other emerging models. Volume data indicates a significant utilization of these models across pharmaceutical and academic research sectors, underscoring their indispensability in preclinical trials.
The competitive landscape is dominated by Charles River Laboratories and Envigo, who are leveraging advanced genetic technology to enhance model efficacy. Regulatory influences, such as the U.S. FDA's guidelines on animal testing, significantly impact market operations, driving the need for compliance and ethical considerations. Looking ahead, the market is poised for growth. Innovations in CRISPR technology and an increasing focus on personalized medicine are anticipated to propel demand for genetically engineered models, presenting lucrative opportunities for market expansion.
North America dominates the market. This is due to robust research infrastructure and significant investment in biomedical research. The United States, in particular, is a major contributor, driven by its advanced healthcare sector and numerous research institutions. Government funding and support for research further enhance the region's market position.
Europe holds a substantial share in the animal model market. The region benefits from a well-established pharmaceutical industry and a strong focus on research and development. Countries like Germany, France, and the United Kingdom are key players, contributing to market growth through innovation and technological advancements.
Asia Pacific is experiencing rapid growth in the animal model market. This is fueled by increasing research activities and rising investments in biotechnology. China and India are at the forefront, with expanding pharmaceutical industries and growing demand for innovative healthcare solutions. The region's focus on improving healthcare infrastructure also supports market expansion.
Latin America is emerging as a promising market for animal models. Brazil and Mexico lead the region, driven by rising investments in research and development. The growing pharmaceutical and biotechnology sectors in these countries contribute to market growth. Government initiatives to support scientific research further bolster the region's potential.
The Middle East and Africa hold a smaller share in the animal model market. However, increasing healthcare awareness and investments in research are driving growth. Countries like South Africa and the UAE are making strides in developing their research capabilities, contributing to the region's gradual market expansion.
Taconic Biosciences, Envigo, Charles River Laboratories, Janvier Labs, Gen Oway, The Jackson Laboratory, Harlan Laboratories, SAGE Labs, Transposagen Biopharmaceuticals, Crown Bioscience, Phoenix Bio, Ozgene, Cyagen Biosciences, Hera Bio Labs, Biocytogen, In Vivos, Psychogenics, Mispro Biotech Services, Axis Pharm, Creative Animodel
National Institutes of Health (NIH), European Commission - Research and Innovation, U.S. Food and Drug Administration (FDA), World Health Organization (WHO), Organisation for Economic Co-operation and Development (OECD) - Science, Technology and Innovation, National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), European Medicines Agency (EMA), The Jackson Laboratory, American Association for Laboratory Animal Science (AALAS), International Council for Laboratory Animal Science (ICLAS), Federation of American Societies for Experimental Biology (FASEB), Society for Laboratory Animal Science (GV-SOLAS), International Society for Transgenic Technologies (ISTT), World Congress on Alternatives and Animal Use in the Life Sciences, American College of Laboratory Animal Medicine (ACLAM), Laboratory Animal Science Association (LASA), International Conference on Animal Models and Experimental Medicine, Animal Models and Human Disease Conference, Society for In Vitro Biology (SIVB), Johns Hopkins University Center for Alternatives to Animal Testing (CAAT)
Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.